Introduction Rybelsus is the brand name of oral semaglutide, a glucagon-like peptide-1 receptor agonist used in the management of type 2 diabetes mellitus. It is pharmacologically important because it is an orally administered GLP-1 receptor agonist, unlike many other GLP-1 receptor agonists that are given by subcutaneous injection. Rybelsus is used along with diet and … Read more
Introduction Sitagliptin is an oral dipeptidyl peptidase‑4 (DPP‑4) inhibitor used to manage type 2 diabetes mellitus (T2DM). It improves glycemic control by enhancing incretin hormone activity, leading to increased insulin secretion and decreased glucagon release in a glucose-dependent manner. Step-by-Step Mechanism of Action Pharmacokinetic Parameters Parameter Value Route Oral Bioavailability ~87% Protein Binding ~38% Metabolism … Read more
Introduction Januvia (sitagliptin) is an oral dipeptidyl peptidase‑4 (DPP‑4) inhibitor used to improve glycemic control in type 2 diabetes mellitus (T2DM). It enhances incretin levels, thereby increasing insulin secretion and lowering glucagon in a glucose-dependent manner. Step-by-Step Mechanism of Action Pharmacokinetic Parameters Parameter Value Route Oral (tablet) Bioavailability ~87% Time to Peak (Tmax) ~1–4 hours Protein … Read more
Introduction Tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for obesity, is a dual GIP/GLP‑1 receptor agonist. This innovative “twincretin” enhances insulin secretion, suppresses glucagon, delays gastric emptying, and promotes satiety. It offers significant HbA₁c reduction and weight loss advantages over GLP‑1 agonists alone. Step-by-Step Mechanism of Action Pharmacokinetic Parameters Parameter Value Route … Read more
